Synapse - Ethan Barnett

Results (31)

Features consistent with a small-cell neuroendocrine like (SC/NE-L) transformation can be readily detected and quantified in circulating tumor cells (CTCs)

Meeting Abstract

Scher, H. I.; Jendrisak, A.; Gilbertson, C.; Gill, A.; Barnett, E.; Gopalan, A.; Keegan, N.; Zaidi, S.; Benoliel, H.; Emily, C.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Circulating tumor cell chromosomal instability and neuroendocrine phenotype by immunomorphology and poor outcomes in men with mCRPC treated with abiraterone or enzalutamide

Journal Article

Brown, L. C.; Halabi, S.; Schonhoft, J. D.; Yang, Q.; Luo, J.; Nanus, D. M.; Giannakakou, P.; Szmulewitz, R. Z.; Danila, D. C.; Barnett, E. S.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer

Meeting Abstract

Scher, H. I.; Armstrong, A. J.; Schonhoft, J. D.; Gill, A.; Zhao, J.; Barnett, E.; Carbone, E.; Lu, J.; Antonarakis, E. S.; Luo, J.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer

Journal Article

Scher, H. I.; Armstrong, A. J.; Schonhoft, J. D.; Gill, A.; Zhao, J. L.; Barnett, E.; Carbone, E.; Lu, J.; Antonarakis, E. S.; Luo, J.; more...
European Journal of Cancer (2021)

Fulltext@MSK | Save

Development of an immunofluorescent AR-V7 circulating tumor cell assay - A blood-based test for men with metastatic prostate cancer

Journal Article

Lu, D.; Krupa, R.; Harvey, M.; Graf, R. P.; Schreiber, N.; Barnett, E.; Carbone, E.; Jendrisak, A.; Gill, A.; Orr, S.; more...
Journal of Circulating Biomarkers (2020)

Fulltext@MSK | Save

Morphology-predicted large-scale transition number in circulating tumor cells identifies a chromosomal instability biomarker associated with poor outcome in castration-resistant prostate cancer

Journal Article

Schonhoft, J. D.; Zhao, J. L.; Jendrisak, A.; Carbone, E. A.; Barnett, E. S.; Hullings, M. A.; Gill, A.; Sutton, R.; Lee, J.; Dago, A. E.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Circulating tumor cells (CTCs) with small-cell like pathology are prevalent in metastatic castration-resistant prostate cancer (mCRPC) and show selective pharmacodynamic reductions in patients treated with platinum but not ARSI or taxane

Meeting Abstract

Scher, H. I.; Jendrisak, A.; Gill, A.; Barnett, E.; Gopalan, A.; Zaidi, S.; Benoliel, H.; Carbone, E.; Byun, J.; Schonhoft, J.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Clinical significance of CTC enumeration on the Epic Sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients treated with AR signaling inhibitors (ARSi)

Meeting Abstract

Schonhoft, J.; Gill, A.; Graf, R. P.; Jendrisak, A.; Barnett, E.; Benoliel, H.; Carbone, E.; Tubbs, A.; Orr, S.; Byun, J.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Prevalence and tissue concordance of BRCA2 copy number loss evaluated by single-cell, shallow whole genome sequencing of circulating tumor cells (CTCs) in castration-resistant prostate cancer (CRPC)